KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Revenue: 2011-2025

Historic Revenue for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $164.9 million.

  • Travere Therapeutics' Revenue rose 162.11% to $164.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $435.8 million, marking a year-over-year increase of 114.22%. This contributed to the annual value of $233.2 million for FY2024, which is 60.55% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Revenue is $164.9 million, which was up 44.05% from $114.4 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Revenue peaked at $164.9 million during Q3 2025, and registered a low of $12.0 million during Q4 2021.
  • For the 3-year period, Travere Therapeutics' Revenue averaged around $67.2 million, with its median value being $54.1 million (2024).
  • In the last 5 years, Travere Therapeutics' Revenue tumbled by 76.46% in 2021 and then skyrocketed by 162.11% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Revenue stood at $12.0 million in 2021, then spiked by 144.49% to $29.3 million in 2022, then skyrocketed by 53.58% to $45.1 million in 2023, then spiked by 65.98% to $74.8 million in 2024, then surged by 162.11% to $164.9 million in 2025.
  • Its last three reported values are $164.9 million in Q3 2025, $114.4 million for Q2 2025, and $81.7 million during Q1 2025.